anti-CEA CAR-T cell therapy (Sorrento/TNK therapeutics/Roger Williams Medical Center)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-CEA CAR-T cell therapy (Sorrento/TNK therapeutics/Roger Williams Medical Center)
Drug Alias Nameanti-CEA CAR-T cell therapy (BDL Products/CARgenix Holdings)anti-CEA CAR-T cell therapy (Harvard/Immunomedics/Beth Israel)anti-CEA CAR-T cell therapy (CEA-positive cancers)anti-CEA designer T cells (Beth Israel Deanconess Medical Center/Immunomedics)anti-CEA designer T-cell therapy (Harvard/Immunomedics/Beth Israel) +[8] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 modulators
TargetsCarcinoembryonic antigen related cell adhesion molecule 5
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisPancreatic Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPreclinical
Originator CompaniesBeth Israel Deaconess Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesTnk Therapeutics Inc3sbio Inc
Inactive CompaniesBeth Israel Deaconess Medical CenterRoger Williams Medical CenterImmunomedics Inc
Active IndicationsSolid tumoursNeoplasm MetastasisPancreatic Neoplasms +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A